NCT07378176 Prognosis of Primary Aldosteronism: A Prospective Cohort Study
| NCT ID | NCT07378176 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xinjiang Medical University |
| Condition | Primary Aldosteronism |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2026-01-30 |
| Primary Completion | 2031-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2026-01-30 with a primary completion date of 2031-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary aldosteronism (PA) is the most common cause of secondary hypertension, and patients with PA have a significantly higher risk of developing cardiovascular and renal complications compared with those with essential hypertension. However, PA remains substantially underdiagnosed and undertreated in clinical practice, and relevant research data on the short-term and long-term prognosis of PA patients in the Chinese population are particularly scarce. This is a multicenter, prospective cohort study designed to systematically collect real-world clinical data of PA patients, including baseline clinical characteristics, etiological subtypes, diagnostic and therapeutic strategies, and long-term follow-up outcomes. Through 5 years of standardized follow-up, this study will analyze the differences in treatment efficacy among PA patients with different pathological subtypes (e.g., adrenal adenoma, adrenal hyperplasia), evaluate the short-term therapeutic efficacy and long-term prognosis of PA patients undergoing different treatment modalities including pharmacotherapy, surgery and interventional therapy, and explore the risk factors for adverse clinical outcomes. Ultimately, it will provide high-quality real-world evidence-based data to optimize the clinical diagnosis and management of PA and improve the long-term prognosis of affected patients.
Eligibility Criteria
Inclusion Criteria: 1. Aged between 18 and 80 years old. 2. Biochemically confirmed diagnosis of Primary Aldosteronism (PA) according to contemporary guidelines (e.g., confirmed positive case detection test and confirmatory test). 3. Voluntary to sign the informed consent. Exclusion Criteria: 1. patients with severe cardiac, hepatic or renal dysfunction; 2. Diagnosis of secondary hypertension other than PA.
Contact & Investigator
Xiang Xie, PhD
STUDY CHAIR
First Affiliated Hospital of Xinjiang Medical University
Frequently Asked Questions
Who can join the NCT07378176 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Primary Aldosteronism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07378176 currently recruiting?
Yes, NCT07378176 is actively recruiting participants. Contact the research team at xiangxie999@sina.com for enrollment information.
Where is the NCT07378176 trial being conducted?
This trial is being conducted at Chengdu, China, Ürümqi, China.
Who is sponsoring the NCT07378176 clinical trial?
NCT07378176 is sponsored by Xinjiang Medical University. The principal investigator is Xiang Xie, PhD at First Affiliated Hospital of Xinjiang Medical University. The trial plans to enroll 5,000 participants.